PANACHE



Production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular, hepatic and joint diseases

Funded by the Horizon 2020 Framework Programme of the European Union

Grant agreement number 858014

01/03/2020 - 29/02/2024

Deliverable number:	D1.2 (D2)
Deliverable title:	Website and logo
Work package:	WP1
Leading partner:	VUB
Participating partners:	UNIGE/FPNS/PROTOQSAR
Due date:	30/04/2020
Submission date:	20/04/2020
Dissemination level:	public

1. Introduction

This deliverable is part of the larger dissemination plan for the project, which will be submitted as a separate deliverable (D1.7) by 28 February 2021. The present deliverable specifically addresses the logo, website, social media and leaflet as major dissemination/communication tools.

2. Logo

The project logo has been designed by VUB. It represents a cellular connexin or pannexin (hemi)channel through which communication occurs (*i.e.* a flow of biochemical messengers). The logo will be used on all dissemination/communication materials.



3. Website

The PANACHE website is available at http://www.panache-project.eu/ and has been developed by the Spanish company Ingenyus. The website will be maintained by VUB and FPNS. The website consists of 6 parts:

- Homepage: gives general information as well as an overview of the different parts of the website.

- Research: gives the project description, project vision, project objectives and project structure.

- Consortium: gives an overview of the different project partners, including links to their websites and ORCID profiles.

- Scientific publications: gives a summary of relevant publications by the project partners, including links to these manuscripts.

- News and events: lists relevant recent news and advertises project events, including links to the websites of these events.

- Contact: full contact information of the project coordinator.



4. Social media

PANACHE is widely visible on social media:

- LinkedIn: FET project PANACHE

- Facebook: PANACHE

- Instagram: @fet_panache

- Twitter: @FET_PANACHE

The social media accounts are maintained by VUB (LinkedIn and Facebook) and FPNS (Instagram and Twitter). Relevant information, such as new publications or announcements of events, are posted on these social media accounts on a frequent basis.

5. Leaflet

The project leaflet has been designed by VUB and is attached. It gives an overview of the project description, project vision, project objectives, and provides general information. The leaflet is intended for a broad public, but in particular for industrial entities. The leaflet will be widely distributed online in different professional networks.

ABOUT PANACHE

PANACHE is a multidisciplinary collaborative project funded by the European Union's Horizon 2020 Future and Emerging Technologies (FET) programme that aims at the development of new anti-inflammatory drugs.

4 years

1 March 2020 - 29 February 2024

3.5 million €

3.503.628,75€ granted by the EU

5 partners

1 industrial and 4 academic partners

3 countries

Belgium, Spain, Switzerland

Project coordinator

Research Group of *In Vitro* Toxicology (IVTD)
Vrije Universiteit Brussel (Belgium)

Partners

Research Group of Organic Chemistry (ORGC)
Vrije Universiteit Brussel (Belgium)

ProtoQSAR S.L. (PROTOQSAR)
ProtoQSAR 2000 S.L. (Spain)

CellCOM Research Group (FPNS)
Institute of Biomedical Research of A Coruña – Fundación Profesor Novoa Santos (Spain)

Research Group of Connexins in Cardiovascular Disease (UNIGE)
Université de Genève (Switzerland)

PANACHE

PANACHE

Production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular, hepatic and joint disease

FOLLOW US

www.panache-project.eu

@fet_panache

FET project PANACHE

@FET_PANACHE

PANACHE

Funded by the Horizon 2020 Framework Programme of the European Union

This project has received funding from the European Union's Horizon 2020 Future and Emerging Technologies programme under grant agreement number 858014

THE PROJECT

The modulation of membrane-bound proteins by drugs is receiving increasing attention from both academia and industry. Among such proteins are pannexin1 (Panx1), connexin (Cx) 43 and Cx32 that form (hemi)channels at the plasma membrane surface. These (hemi)channels mediate cellular communication and have emerged as key players in inflammation. This carries translational relevance, as (hemi)channel inhibition could represent an innovative strategy for the treatment of a plethora of diseases. However, a hurdle in clinical exploration is the lack of appropriate (hemi)channel inhibitors.

PANACHE therefore is a timely project, since it will generate a novel generation of (hemi)channel inhibitors as potential drugs. This will be accomplished by joining academic and industrial scientists from the chemical, chemo-informatics and biomedical fields as well as by relying on *in vitro* and *in silico* studies, animal experimentation and testing human material.

PANACHE will allow taking a leap forward to the realization of its long-term vision, namely the production of metabolically robust and selective (hemi)channel inhibitors that can be used for the establishment of a generic approach to synergize current therapy of hard-to-treat inflammatory diseases.



OUR OBJECTIVES



OUR VISION

The long-term vision of PANACHE is the production of an unprecedented set of (hemi)channel inhibitors that can be used for the establishment of a mechanistically anchored and generic approach to synergize current therapy of hard-to-treat inflammatory diseases. For proof-of-concept purposes, focus will be put on inflammatory disorders in the cardiovascular system, liver and joints.

The scope of PANACHE is, however, much broader, as these innovative (hemi)channel inhibitors are anticipated to be equally applicable for the therapy of a number of other inflammatory disorders in which Panx1, Cx43 and Cx32 are known to be involved. Such applications will be tested in follow-up initiatives of PANACHE, thereby realizing its long-term vision.